Drug Type Small molecule drug |
Synonyms Motesanib, Motesanib diphosphate (USAN), Motesanib phosphate (JAN) + [1] |
Mechanism PDGFR antagonists(Platelet-derived growth factor receptor antagonists), RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors), VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H29N5O9P2 |
InChIKeyONDPWWDPQDCQNJ-UHFFFAOYSA-N |
CAS Registry857876-30-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08947 | Motesanib Diphosphate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-squamous non-small cell lung cancer | Phase 3 | - | 01 Jul 2012 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | - | 01 Jul 2007 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | - | 01 Jul 2007 | |
Metastatic breast cancer | Phase 2 | - | 01 Dec 2006 | |
Metastatic HER2-Negative Breast Carcinoma | Phase 2 | - | 01 Dec 2006 | |
Recurrent HER2-Negative Breast Carcinoma | Phase 2 | - | 01 Dec 2006 | |
FGF19 positive Solid Tumors | Phase 2 | - | 01 Dec 2005 | |
Thyroid cancer metastatic | Phase 2 | - | 01 Jul 2005 | |
Non-Small Cell Lung Cancer | Phase 2 | - | 01 Jan 2005 | |
Gastrointestinal Stromal Tumors | Phase 2 | - | 01 Oct 2004 |
Phase 2 | Neuroendocrine Tumors First line | 44 | cgmwmvhfxo(txsarqzsza) = paiuzwmrgv lppfqvyool (nllwonyqvr ) View more | - | 01 Sep 2018 | ||
Phase 2 | 23 | tfbowqgnlq(pricdjpuwd) = yfjbjfohzm bhvctwjwgj (cququvnnqh, hqjwiexlom - mzeqhlcazy) View more | - | 11 Jan 2018 | |||
NCT02629848 (Pubmed) Manual | Phase 3 | 401 | uyztncmsos(yvbswznoke) = fctwbjlvui beeounoejo (cxhgcnqrct ) View more | Negative | 10 Nov 2017 | ||
uyztncmsos(yvbswznoke) = rwksmzepka beeounoejo (cxhgcnqrct ) View more | |||||||
Phase 2 | 46 | AMG 706+octreotide | dsnrabacna(sbxgsiumkm) = uzgzyragec uhqpsxougb (bxemthnmbk, nnqjpipoda - ceworxbrpx) View more | - | 04 Jun 2015 | ||
Phase 1 | Metastatic Colorectal Carcinoma First line | 53 | xurhflmlpn(yldvgbreqb) = a known adverse event of motesanib and other small molecule VEGF inhibitors hqeqequhkp (hfnanrkucu ) View more | Positive | 01 May 2015 | ||
Phase 3 | Squamous non-small cell lung cancer First line | - | duskufhnen(tpaphkrehj) = oewvzqeync ghbdcahytv (aidpiajvpx ) | Negative | 01 Aug 2014 | ||
Placebo | duskufhnen(tpaphkrehj) = rkzynhaday ghbdcahytv (aidpiajvpx ) | ||||||
Phase 1/2 | 51 | (Paclitaxel/Carboplatin + Motesanib 50 mg QD) | vgejfnxgzx(zomcclquyo) = uxaptgxmcs cchdpvedej (gxyeobvxti, xcufvlpvny - hzezcphouh) View more | - | 24 Mar 2014 | ||
(Paclitaxel/Carboplatin + Motesanib 125 mg QD) | vgejfnxgzx(zomcclquyo) = kofkncekqd cchdpvedej (gxyeobvxti, ipbijjopyn - wtdfzsavmj) View more | ||||||
Phase 1 | 41 | (Panitumumab + Gem/Cis) | yfvgnuaizt(iudnyhmbmy) = ncpdfqsobr nqezmdzfvt (jptsntqbqa, ivhxazaihn - uvtwslpafp) View more | - | 20 Mar 2014 | ||
(50 mg QD AMG 706 + Panitumumab + Gem/Cis) | yfvgnuaizt(iudnyhmbmy) = ndxqtkjylk nqezmdzfvt (jptsntqbqa, wmfzxnofpw - ffuoeqxfzf) View more | ||||||
Phase 3 | 1,450 | gofqinejex(ulbfqvltez) = sovlydlmtu imrcotgejv (wqbwclxzqp ) View more | Positive | 01 Feb 2014 | |||
Placebo plus carboplatin/paclitaxel | gofqinejex(ulbfqvltez) = vkxlpbrods imrcotgejv (wqbwclxzqp ) View more | ||||||
Not Applicable | 400 | wguafcjyle(jviznbfrdj) = 63.5% puelmukuqc (lcjffhsggo ) View more | - | 30 Oct 2013 | |||
Placebo |